




RealRate

PHARMACEUTICAL 2021

Q BioMed Inc.
Rank 407 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2021

Q BioMed Inc.
Rank 407 of 409

The relative strengths and weaknesses of Q BioMed Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Q BioMed Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 457% points. The greatest weakness of Q BioMed Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 4,140% points.

The company's Economic Capital Ratio, given in the ranking table, is -4,819%, being 4,464% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	223
Cost of Goods Sold	326
Intangible Assets	400
Liabilities, Current	1,699
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	347
Other Liabilities	0
Other Net Income	0
Property and Equipment	0
Research and Development	1,880
Revenues	30
Selling, General and Administrative Expense	10,969

Output Variable	Value in 1000 USD
Assets	623
Liabilities	1,699
Expenses	13,522
Stockholders Equity	-1,075
Net Income	-13,492
Comprehensive Net Income	-13,492
Economic Capital Ratio	-4,819%

